Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

That's less than the cost of other biologics for severe asthma like GlaxoSmithKline's IL-5 inhibitor Nucala (mepolizumab) and Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab ...

Some of these are mentioned below. How much Dupixent costs is based on several factors. These can include your prescribed treatment regimen, your insurance plan, the pharmacy you use, and your ...

Dupixent pen and syringe are two different devices used to inject the drug. They’re prefilled with the same amount of Dupixent and share other features, but certain factors make the pen easier ...

Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

It’s likely that patients with the most severe disease will be the first to receive Dupixent in the UK and other EU markets. England’s cost effectiveness watchdog NICE is in the early stages ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

DUPIXENT sales contribute to Regeneron's revenue ... US annually and perhaps 5-10% fall into the high risk category. The cost for a supply of 7mL for IV infusion is $11,178. While this is a ...